Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome.
Carvajal
Richard D
RD
Ilson
David H
DH
Noy
Ariela
A
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy; D002227:Carbazoles / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D002227:Carbazoles; D007211:Indoles; D059004:Topoisomerase I Inhibitors; C121395:edotecarin